The Night of Vision 2024: A Spotlight on Usher Syndrome
The annual La Nit de la Visió event, organized by Save Sight Now Europe,…
News
Breakthrough in USH1B Research: Advancing MYO7A Therapy Development
Understanding MYO7A to Advance USH1B Therapies The goal of this project is twofold: 1.…
Spain Releases First Report on Rare Visual Diseases
Retina Murcia Association launches with its Research Group on Rare Visual Diseases (GISERV) the…
We attended EURETINA 2024 in Barcelona
Save Sight Now Europe attended Euretina’24 in Barcelona from 19-22nd of September It was…
Collaborative Visit at L’Institut de la Vision, Paris
Save Sight Now Europe joined the team at L’Institut de la Vision, Paris, to…
AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B – First Patient Dosed
AAVantgarde Announces LUCE-1 Trial for Usher Syndrome Type 1B and First Patient Dosed AAVantgarde…
RIWC 2024 (Retina International World Congress)
Championing Usher Syndrome: Highlights from RIWC24 in Dublin We are thrilled to share our…
ARVO 2024 (The Association for Research in Vision and Ophthalmology Conference)
Save Sight Now Europe has been at ARVO 2024 to Champion Advances in Retinal…
AAVantgarde Bio Unveils LUCE-1 Clinical Trial Design for Usher Syndrome type 1B Gene Therapy
AAVantgarde Bio Unveils Innovative LUCE-1 Clinical Trial Design (for USH1B) at Gene Therapy Summit…
Restoring hearing loss – leading advancement in OTOF gene-related deafness
First gene therapy treatment for a hereditary form of deafness in the USA The…